Noriaki Yoshida

Dr. Noriaki Yoshida

Radiation Effects Research Foundation
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2019 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KYKengo Yoshida
Kengo Yoshida
BFBenjamin French
Benjamin French
NYNoriaki Yoshida
Noriaki Yoshida
AHAyumi Hida
Ayumi Hida
WOWaka Ohishi
Waka Ohishi
YKYoichiro Kusunoki
Yoichiro Kusunoki

5 February 2016 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
NYNoriaki Yoshida
Noriaki Yoshida
HMHiroaki Miyoshi
Hiroaki Miyoshi
TKTakeharu Kato
Takeharu Kato
MSMamiko Sakata‐Yanagimoto
Mamiko Sakata‐Yanagimoto
DNDaisuke Niino
Daisuke Niino
KOKoichi Ohshima
Koichi Ohshima

14 July 2015 in Cancer Science
Verified
Journal Article
Open access
PDF file
NYNoriaki Yoshida
Noriaki Yoshida
STShinobu Tsuzuki
Shinobu Tsuzuki
KKKennosuke Karube
Kennosuke Karube
TTTaishi Takahara
Taishi Takahara
MSMiyuki Suguro
Miyuki Suguro
MSMasao Seto
Masao Seto
Peripheral T‐cell lymphomas (PTCL) are a heterogeneous group of non‐Hodgkin lymphomas with poor prognosis. Their molecular pathogenesis has not been entirely elucidated. We previously showed that 6q24 is one of the most frequently deleted regions in primary thyroid T‐cell lymphoma. In this study, we extended the analysis to other subtypes of PTCL and performed functional assays to identify the causative genes of PTCL that are located on 6q24. Genomic loss of 6q24 was observed in 14 of 232 (6%) PTCL cases. The genomic loss regions identified at 6q24 always involved only two known genes, STX11 and UTRN. The expression of STX11, but not UTRN, was substantially lower in PTCL than in normal T‐cells. STX11 sequence analysis revealed mutations in two cases (one clinical sample and one T‐cell line). We further analyzed the function of STX11 in 14 cell lines belonging to different lineages. STX11 expression only suppressed the proliferation of T‐cell lines bearing genomic alterations at the STX11 locus. Interestingly, expression of a novel STX11 mutant (p.Arg78Cys) did not exert suppressive effects on the induced cell lines, suggesting that this mutant is a loss‐of‐function mutation. In addition, STX11‐altered PTCL not otherwise specified cases were characterized by the presence of hemophagocytic syndrome (67% vs 8%, P = 0.04). They also tended to have a poor prognosis compared with those without STX11 alteration. These results suggest that STX11 plays an important role in the pathogenesis of PTCL and they may contribute to the future development of new drugs for the treatment of PTCL.

3 January 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
NANaoko Asano
Naoko Asano
HMHiroaki Miyoshi
Hiroaki Miyoshi
TKTakeharu Kato
Takeharu Kato
JSJoji Shimono
Joji Shimono
NYNoriaki Yoshida
Noriaki Yoshida
MSMasao Seto
Masao Seto

22 June 2020 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
EYEriko Yanagida
Eriko Yanagida
HMHiroaki Miyoshi
Hiroaki Miyoshi
MTMai Takeuchi
Mai Takeuchi
NYNoriaki Yoshida
Noriaki Yoshida
KNKazutaka Nakashima
Kazutaka Nakashima
KOKoichi Ohshima
Koichi Ohshima

24 September 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KYKyohei Yamada
Kyohei Yamada
HMHiroaki Miyoshi
Hiroaki Miyoshi
NYNoriaki Yoshida
Noriaki Yoshida
JSJoji Shimono
Joji Shimono
KSKensaku Sato
Kensaku Sato
KOKoichi Ohshima
Koichi Ohshima